Halaven
RNA-Binding Protein FUS, Breast, Liposarcoma
Treatment
5 FDA approvals
0 Active Studies for Halaven
Treatment for
RNA-Binding Protein FUS
What is Halaven
Eribulin
The Generic name of this drug
Treatment Summary
Eribulin is a medication used to treat metastatic breast cancer that has not responded to previous chemotherapy treatments. It was derived from a type of marine sponge and is also being studied for its potential to treat other advanced solid tumors.
Halaven
is the brand name
Halaven Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Halaven
Eribulin
2010
2
Approved as Treatment by the FDA
Eribulin, also known as Halaven, is approved by the FDA for 5 uses which include Metastatic Liposarcoma and refractory, metastatic Breast cancer .
Metastatic Liposarcoma
refractory, metastatic Breast cancer
Breast
Liposarcoma
RNA-Binding Protein FUS
Effectiveness
How Halaven Affects Patients
This drug has a predictable effect that remains the same when increased doses are taken.
How Halaven works in the body
Eribulin stops cells from dividing by blocking the growth of microtubules. This blockage disrupts the mitotic spindles, which are essential for cell division, and eventually leads to cell death.
When to interrupt dosage
The prescribed measure of Halaven depends upon the diagnosed disorder, including Metastatic Liposarcoma, Breast and RNA-Binding Protein FUS. The dosage amount is contingent upon the procedure of delivery (e.g. Injection, solution or Solution - Intravenous) as shown in the table beneath.
Condition
Dosage
Administration
RNA-Binding Protein FUS
, 0.44 mg/mL, 0.5 mg/mL
, Solution, Intravenous, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous
Breast
, 0.44 mg/mL, 0.5 mg/mL
, Solution, Intravenous, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous
Liposarcoma
, 0.44 mg/mL, 0.5 mg/mL
, Solution, Intravenous, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous
Warnings
Halaven has one contraindication, so it ought not to be taken while encountering the conditions outlined in the table below.
Halaven Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Halaven.
Common Halaven Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Eribulin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Acteoside
Major
The risk or severity of adverse effects can be increased when Eribulin is combined with Acteoside.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Eribulin is combined with Antilymphocyte immunoglobulin (horse).
Bacillus calmette-guerin substrain russian BCG-I live antigen
Major
The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Eribulin.
Baricitinib
Major
The risk or severity of adverse effects can be increased when Eribulin is combined with Baricitinib.
Halaven Toxicity & Overdose Risk
Eribulin can cause damage to the peripheral nerves, which is the most common side effect that leads to people stopping the medication. In animal testing, a single dose of 0.75 mg/kg was fatal for rats, and two doses of 0.075 mg/kg was fatal for dogs. The amount of eribulin that caused no harm in rats and dogs was 0.015 and 0.0045 mg/kg per day, respectively.
Halaven Novel Uses: Which Conditions Have a Clinical Trial Featuring Halaven?
Two active trials are currently investigating the potential of Halaven to treat Breast Cancer, RNA-Binding Protein FUS and Metastatic Liposarcoma.
Condition
Clinical Trials
Trial Phases
Breast
0 Actively Recruiting
Liposarcoma
0 Actively Recruiting
RNA-Binding Protein FUS
0 Actively Recruiting
Halaven Reviews: What are patients saying about Halaven?
5
Patient Review
2/10/2011
Halaven for Breast Cancer that has Spread to Another Part of the Body
4.7
Patient Review
10/31/2011
Halaven for Breast Cancer that has Spread to Another Part of the Body
4.3
Patient Review
11/13/2011
Halaven for Breast Cancer that has Spread to Another Part of the Body
4
Patient Review
6/7/2011
Halaven for Breast Cancer that has Spread to Another Part of the Body
4
Patient Review
2/2/2016
Halaven for Breast Cancer that has Spread to Another Part of the Body
Patient Q&A Section about halaven
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is HALAVEN chemotherapy?
"Eribulin mesylate, also known by its brand name Halaven, is a chemotherapy drug."
Answered by AI
What is HALAVEN used for?
"HALAVEN is prescribed to adults with breast cancer that has metastasized to other parts of the body. It is usually given after the patient has received other types of anticancer medicines."
Answered by AI
How effective is HALAVEN?
"Patients with advanced liposarcoma who were treated with HALAVEN lived an average of 15.6 months compared with patients treated with the other chemotherapy, who lived an average of 8.4 months. This means that patients who received HALAVEN chemotherapy lived 86% longer, on average, than patients who received the other chemotherapy."
Answered by AI
Does HALAVEN cause hair loss?
"The most common side effects of HALAVEN in adults with breast cancer include neutropenia, anemia, weakness or tiredness, alopecia, nausea, and constipation."
Answered by AI